CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
American Ginseng rootdrug
Likely dose
American Ginseng root 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00631852
NCT00631852Phase 2Completed
CompareCT.gov

A Phase II Biomarker Trial of Gelatin Encapsulated Extract of American Ginseng Root (LEAG) in Breast Cancer

Southern Illinois University·interventional·Posted Mar 10, 2008·Updated May 12, 2026

In Brief

A Phase 2 clinical trial evaluating American Ginseng root for Breast Cancer. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study was designed to explore the changes brought about by gelatin encapsulated extract of American Ginseng Root (LEAG) in breast cancer tumors and surrounding normal breast epithelial cells. Various tumor biomarkers, as well as inflammatory mediators, will be examined in tissue following LEAG treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 10, 2008
Enrollment StartFeb 1, 2008
Primary CompletionJun 30, 2019
TodayJul 2, 2026
Enrollment to primary: 11.4 yearsPosted 18.3 years ago

Interventions

American Ginseng rootdrug

four, 250mg tablets daily 5-14 days prior to surgery